StudyFinder
MT2022-56: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
Recruiting
The purpose of this study is to test the safety of FT576 at different doses and schedules and to understand the way the body processes and responds to FT576. The study will also find out what effects FT576, when given alone (also called monotherapy) or in combination with an anti-cancer drug (called a monoclonal antibody), may have on you and your cancer. FT576 is a type of cell product made up of “natural killer” or NK cells. NK cells are a type of immune blood cell that are known to attack cancer cells.
Male or Female
18 years and over
Inclusion Criteria:
• diagnosis of multiple myeloma after 3 or more previous treatments
• able to complete activities of daily living with minimal help
Exclusion Criteria:
• history of significant heart disease
• low red or white blood counts
• abnormal liver function tests
Cancer
Multiple Myeloma, Myeloma, Clinics and Surgery Center (CSC)